Calamos Advisors LLC Increases Position in Masimo Corporation (NASDAQ:MASI)

Calamos Advisors LLC lifted its holdings in shares of Masimo Corporation (NASDAQ:MASI - Free Report) by 44.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 23,449 shares of the medical equipment provider's stock after acquiring an additional 7,169 shares during the quarter. Calamos Advisors LLC's holdings in Masimo were worth $3,907,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Jones Financial Companies Lllp bought a new stake in shares of Masimo during the 4th quarter worth $27,000. Farther Finance Advisors LLC raised its position in Masimo by 128.9% in the first quarter. Farther Finance Advisors LLC now owns 206 shares of the medical equipment provider's stock worth $35,000 after acquiring an additional 116 shares during the period. EverSource Wealth Advisors LLC boosted its stake in Masimo by 40.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider's stock valued at $37,000 after acquiring an additional 64 shares during the last quarter. Smartleaf Asset Management LLC grew its position in shares of Masimo by 31.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 250 shares of the medical equipment provider's stock valued at $42,000 after acquiring an additional 60 shares during the period. Finally, SBI Securities Co. Ltd. bought a new stake in shares of Masimo in the 4th quarter worth approximately $46,000. 85.96% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Piper Sandler reissued an "overweight" rating and set a $200.00 price objective (down from $215.00) on shares of Masimo in a report on Wednesday, May 7th. Wells Fargo & Company cut their price target on Masimo from $205.00 to $190.00 and set an "overweight" rating for the company in a research note on Wednesday, May 7th. Needham & Company LLC restated a "hold" rating on shares of Masimo in a research note on Thursday, April 10th. Wall Street Zen downgraded shares of Masimo from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. Finally, BTIG Research set a $193.00 price target on shares of Masimo and gave the company a "buy" rating in a research note on Wednesday, May 7th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $191.60.

Masimo Stock Down 2.1%

MASI opened at $167.67 on Friday. The firm has a market capitalization of $9.09 billion, a P/E ratio of -18.28 and a beta of 1.19. Masimo Corporation has a one year low of $101.61 and a one year high of $194.88. The company has a fifty day moving average price of $161.89 and a 200-day moving average price of $166.46. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.17 and a quick ratio of 1.62.

Masimo (NASDAQ:MASI - Get Free Report) last posted its earnings results on Tuesday, May 6th. The medical equipment provider reported $1.36 EPS for the quarter, topping the consensus estimate of $1.24 by $0.12. Masimo had a positive return on equity of 22.56% and a negative net margin of 25.06%. The business had revenue of $372.00 million during the quarter, compared to analysts' expectations of $367.79 million. During the same period in the previous year, the business earned $0.77 earnings per share. The firm's revenue was down 24.5% on a year-over-year basis. Equities research analysts expect that Masimo Corporation will post 4.1 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, COO Bilal Muhsin sold 10,000 shares of the stock in a transaction on Monday, May 12th. The shares were sold at an average price of $163.28, for a total value of $1,632,800.00. Following the transaction, the chief operating officer owned 24,172 shares of the company's stock, valued at $3,946,804.16. This represents a 29.26% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 9.70% of the stock is currently owned by corporate insiders.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.

Want to see what other hedge funds are holding MASI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Masimo Corporation (NASDAQ:MASI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.